HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

suritozole

Also Known As:

2,4-dimethyl-5-(3-fluorophenyl)-3H-1,2,4-triazole-3-thione; MDL 26,479; MDL 26479; MDL-26479

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - suritozole: 2

Related Diseases

1.	Traumatic Brain Injuries (Traumatic Brain Injury) 11/01/1995 - "Chronic postinjury administration of MDL 26,479 (Suritozole), a negative modulator at the GABAA receptor, and cognitive impairment in rats following traumatic brain injury." 11/01/1995 - "The present experiment examined the efficacy of postinjury administration of MDL 26,479 (Suritozole), a negative modulator at the gamma-aminobutyric acidA (GABAA) receptor that enhances cholinergic function, in attenuating spatial memory deficits after traumatic brain injury in the rat. "
2.	Cognitive Dysfunction 11/01/1995 - "Chronic postinjury administration of MDL 26,479 (Suritozole), a negative modulator at the GABAA receptor, and cognitive impairment in rats following traumatic brain injury."
3.	Memory Disorders (Memory Loss) 05/01/1997 - "MDL 26479 is a new drug undergoing clinical evaluation for the treatment of depression and for memory loss associated with Alzheimer's disease. "
4.	Alzheimer Disease (Alzheimer's Disease) 05/01/1997 - "MDL 26479 is a new drug undergoing clinical evaluation for the treatment of depression and for memory loss associated with Alzheimer's disease. "

Related Drugs and Biologics

1.	suritozole
2.	Cholinergic Agents (Cholinergics)